Psyence Biomedical Ltd Surges on Clinical Trial Progress
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 09 Dec 25
Psyence Biomedical Ltd's stock rose by 12.43%, crossing above the 5-day SMA, reflecting positive investor sentiment.
The company highlighted significant achievements in 2025, including successful patient recruitment for a Phase IIb clinical trial aimed at improving mental health treatment in palliative care. This progress is expected to enhance its competitive position in the market.
With regulatory support and a unique focus on longevity science, Psyence is well-positioned to attract further investor interest, potentially leading to sustained growth.
Analyst Views on PBM
About PBM
Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The Company is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. It is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
